



NON-DEAL ROADSHOW

SEPTEMBER 2021

Nasdaq: LGND



SAFE HARBOR STATEMENT


The following presentation contains forward-looking statements by Ligand and its partners that involve risks and uncertainties and reflect Ligand's and its partners' judgment as of the date of this presentation. Words such as "plans," "believes," "expects," "projects," "could," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, expectations regarding research and development programs, the timing of the initiation or completion of preclinical studies and clinical trials by Ligand and its partners, expectations regarding product approvals and potential for future revenue growth, and launches by Ligand or its partners and the timing thereof, total addressable market for antibodies. Actual events or results may differ from Ligand's expectations due to risks and uncertainties inherent in Ligand's business, including the inherent risks of clinical development and regulatory approval of product candidates, including that FDA or foreign regulatory authorities may not agree with our or our partners' conclusions regarding the results of clinical trials; Ligand may be unable to successfully integrate operations from acquired businesses or may face other difficulties as a result of acquisitions such as strain on operational resources; the total addressable market for antibodies or other therapeutics may be smaller than estimated; we face competition with respect to our technology platforms, including OmniAb, which may demonstrate greater market acceptance or superiority; partnered commercial products may not perform as expected; Ligand relies on collaborative partners for milestone and royalty payments, royalties, materials revenue, contract payments and other revenue projections; Ligand does not have contractual relationships with certain parties identified as partners and is dependent on WuXi Biologics Ireland Limited to enforce any contractual rights such as payment of royalties or milestones; the possibility that Ligand's and its partners' drug candidates might not be proved to be safe and efficacious and uncertainty regarding the commercial performance of Ligand's and/or its partners' products; and other risks and uncertainties described in its public filings with the Securities and Exchange Commission, available at www.sec.gov. Additional risks may apply to forward-looking statements made in this presentation. Information regarding partnered products and programs comes from information publicly released by our partners. This presentation describes the typical roles and responsibilities of Ligand and our partners and is not intended to be a complete description in all cases. Our trademarks, trade names and service marks referenced herein include Ligand, Captisol, Pelican Expression Technology, OmniAb, OmniChicken, OmniRat, OmniMouse, OmniFlic, OmniClic and OmniTaur. Each other trademark, trade name or service mark appearing in this presentation belongs to its owner.

The process for reconciliation between the non-GAAP adjusted financial numbers presented on slide 12 and the corresponding GAAP figures is shown in the earnings press release for the second quarter ended June 30, 2021 available at <https://investor.ligand.com/press-releases>. However, other than with respect to total revenues, the Company only provides financial guidance on an adjusted basis and does not provide reconciliations of such forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Ligand disclaims responsibility for any statement by a person other than its employees and the views expressed by persons other than Ligand employees do not necessarily reflect the views of Ligand.

Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect our good faith beliefs (or those of the indicated third parties) and speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Ligand undertakes no obligation to revise or update this presentation to reflect events or circumstances or update third party research numbers after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934.

ABOUT LIGAND

3



LIGAND ADDS VALUE . . .

. . . JUST ASK OUR MORE THAN 130 PARTNERS

Our research and technology help partners...



Discover medicines



Improve safety




Reduce costs















Ligand's technology and R&D support entitles us to **share in revenue of partners through royalties**

PARTNERED PIPELINE

BROAD PORTFOLIO WITH OVER 130 DIFFERENT PARTNERS



PARTNERED PIPELINE SNAPSHOT

| Partner | Program | Therapy Area | Technology | Preclinical | Phase 1 | Phase 2 | Phase 3 | Approved |
|--|----------------------|----------------|------------|--|---------|---------|---------|----------|
|  AMGEN | <i>Kyprolis</i> ® | Oncology | Captisol | | | | | |
|  ACROTECH BIOPHARMA | <i>EVOMELA</i> ® | Oncology | Captisol | | | | | |
|  GILEAD | <i>Veklury</i> ® | Infection | Captisol | | | | | |
|  Alvogen | <i>Teriparatide</i> | Osteoporosis | Pelican | | | | | |
|  SERUM INSTITUTE OF INDIA PVT. LTD. | <i>Pneumosil</i> ® | Infection | Pelican | | | | | |
|  Jazz Pharmaceuticals | <i>Rylaze</i> ™ | Oncology | Pelican | | | | | |
|  MERCK | <i>Vaxneuvance</i> ™ | Infection | Pelican | | | | | |
|  gloria 誉衡生物 ⁽¹⁾ | Zimberelimab | Oncology | OmniAb | | | | | |
| Multiple Additional Partners and Programs | | | | Includes: ZULRESSO (Sage), MINNEBRO (Daiichi-Sankyo), NEXTERONE (Baxter), DUAVEE (Pfizer), and 22 Others | | | | |
|  TRAVERE THERAPEUTICS | Sparsentan | Kidney Disease | NCE | | | | | |
|  基石药业 (1) CSTONE PHARMACEUTICALS | Sugemalimab | Oncology | OmniAb | | | | | |
|  ARCUS BIOSCIENCES | Zimberelimab | Oncology | OmniAb | | | | | |
|  MARINUS PHARMACEUTICALS | Ganaxolone-IV | CNS | Captisol | | | | | |
|  Verona Pharma | Ensifentrine | Respiratory | NCE | | | | | |
|  NOVAN | SB206 | Infection | NCE | | | | | |
| Multiple Additional Partners and Programs | | | | Includes 17 additional Phase 3 or Pivotal assets | | | | |
| Multiple Partners and Programs | | | | 26 Phase 2 assets | | | | |
| Multiple Partners and Programs | | | | 29 additional Phase 1 assets | | | | |













Partnered pipeline also includes >200 preclinical and discovery programs

Status of partnered programs from information released by our partners and from clinicaltrials.gov

(1) Partnership is through a Ligand license with WuXi Biologics

FIVE RECENT APPROVALS











OUR PROPRIETARY PLATFORMS ARE ENABLING IMPORTANT APPROVALS AND POSITIONING LIGAND FOR SUBSTANTIAL GROWTH OF ROYALTY REVENUE

| PROGRAM | PARTNER | TECH PLATFORM | APPROVAL |
|--|--|--|---------------|
|  <small>Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed, 10-Valent)</small> |  <small>SERUM INSTITUTE OF INDIA</small> <small>Cyrus Poonawalla Group</small> |  <small>P. fluorescens expression technology</small> | December 2020 |
|  <small>asparaginase erwinia chrysanthemi (recombinant)-rywn for injection 10mg/0.5mL per vial</small> |  <small>Jazz Pharmaceuticals</small> |  <small>P. fluorescens expression technology</small> | June 2021 |
|  <small>Kyprollis (carfilzomib) for injection</small> |  <small>BeiGene AMGEN</small> |  <small>CAPTISOL®</small> | July 2021 |
|  <small>Vaxneuvance™ Pneumococcal 15-valent Conjugate Vaccine</small> |  <small>MERCK</small> |  <small>P. fluorescens expression technology</small> | July 2021 |
|  <small>Zimmerelimab</small> |  <small>gloria 誉衡生物 BIOSCIENCES</small> |  <small>OmniAb®</small> | August 2021 |

Not approved in all jurisdictions

WE EXPECT A SUBSTANTIAL CALENDAR OF LATE-STAGE EVENTS

Next Six Quarters of Potential Events

| Approvals | NDA Submissions | | Major Data Events | |
|---|--|--|---|--|
| Sugemalimab Approval (China)  | Sparsentan NDA Submissions  | Sugemalimab NDA Submission (US)  | Ensifentrine Phase 3 data  | VK2809 Phase 2 data  |
| Teriparatide TE (US)  | Erwinia asparaginase MAA Submission  | Vaxneuvance™ Pediatric Submission  | Ganaxalone-IV Phase 3 data  | Lasofoxifene Phase 2 data  |

Based on clinicaltrials.gov or partner disclosures

RECENT RYLAZE™ APPROVAL

APPROVED IN U.S. ON JUNE 30, 2021



9



RELY ON RYLAZE—THE ONLY RECOMBINANT *ERWINIA* ASPARAGINASE APPROVED FOR THE TREATMENT OF ALL/LBL¹

- Recombinant Erwinia asparaginase for ALL/LBL, enabled by the Pelican Expression Technology
 - High quality, reliable supply for a major unmet need
 - \$>200 M market potential in US alone
- Approved on June 30; launch on July 15, 2021
 - 1+ year supply available
- Jazz launch focused on pediatric oncologist; majority of ALL incidence in children
 - Education and awareness campaigns on-going
- National Comprehensive Cancer Network® added Rylaze™ to ALL Clinical Practice Guidelines
- EU filing anticipated in 2022; Japan submission to follow


CRM197 - PELICAN PARTNERSHIP

VAXNEUVANCE™ PNEUMOCOCCAL VACCINE APPROVAL



- Vaxneuvance™ approved July 16, 2021, for the prevention of pneumococcal disease in adults
 - 15-valent pneumococcal vaccine utilizing Ligand's CRM197 vaccine carrier protein produced using the Pelican Expression Technology platform
- Vaxneuvance will compete directly with Pfizer's Prevnar13® (2020 worldwide sales of \$5.9 B) and recently-approved Prevnar20™
- Vaxneuvance sBLA for pediatric population anticipated by year-end, 1-2 years ahead of estimated Prevnar20 pediatric submission
 - If approved, market opportunity expected to more than double
- Merck's follow-on pneumococcal vaccine candidate V116, currently in Phase 2, also uses CRM197 produced using Pelican Expression Technology™

NOW APPROVED



DISCOVERY & MANUFACTURING PLATFORMS

CUTTING-EDGE, ROYALTY-BEARING TECHNOLOGIES THAT MAKE MAJOR LIFE-SAVING GLOBAL DRUGS POSSIBLE

Manufacturing/CMC

PELICANTM
P. fluorescens expression technology

Making production possible

Antibody Discovery

OmniAb[®]

Delivering fully human antibodies

**Ligand's business model is based on providing drug discovery platforms,
completing early-stage drug development and partnering**

2021 FINANCIAL REVIEW

GUIDANCE GIVEN AT Q2 EARNINGS RELEASE

40%+

2021 revenue growth

30%+

2021 adjusted EPS growth

**\$265 - \$275
million**

Total Revenue

Royalty and Milestone combined exceeding previous \$91 million expectations

75% - 80%

Gross Margin

Strong gross margins even with outsized Captisol contribution

**\$80 - \$85
million**

Cash Expenses

Cash operating expenses in line with original expectations

\$5.80 - \$6.05

Adjusted EPS

Adjusted EPS driven by high cash flow and low share count

PELICAN EXPRESSION TECHNOLOGY

Overview



SOLVING OUR INDUSTRY'S PROTEIN PRODUCTION CHALLENGES

Our Pelican Expression Technology™ Platform uniquely enables **complex protein drug production** with quality and efficiency

- Global therapeutic protein market estimated at **\$100B+** and growing
- Clinical and commercial success achieved with protein therapeutics is **increasing demand for technologies** that deliver competitively positioned products with desired properties
- Protein therapeutics are often of a physical size that is orders of magnitude larger than small-molecule drugs and exhibit **complex secondary, tertiary and quaternary structures that must be maintained in production**

PELICAN™
P. fluorescens expression technology




A UNIQUE VALUE-DRIVING PLATFORM

- Industrial legacy from Mycogen Corp, Dow Chemical and Pfenex
- Platform delivers **significant competitive advantages to our partners**, including:
 - ✓ Speed to identifying production strain
 - ✓ Success rates resulting in minimization of time/cost of development
 - ✓ Efficient production
 - ✓ Decreased long-term cost-of-goods
- Significant institutional knowledge of protein production developed over **three decades**

PELICAN[™]
P. fluorescens expression technology


Pelican Expression Platform[™] has given rise to approved products and has maintained a **success rate of over 80%** in expressing a variety of “lead” protein candidates



PELICAN: THE INDUSTRY'S DEEPEST PROKARYOTIC PROTEIN PRODUCTION PLATFORM

P. fluorescens: A GRAM-NEGATIVE, NON-PATHOGENIC, METABOLICALLY VERSATILE ORGANISM

- Genomic, RNAseq, and proteomics data leveraged to engineer host strains and design expression plasmids
- Animal origin-free and used with antibiotic-free processes
- High-throughput growth and test methods
- Rapid, effective, fermentation and purification development/scale-up expedite program timelines



Clinically and **recently commercially validated** with approved therapeutics and vaccines

PELICAN EXPRESSION TECHNOLOGY PLATFORM

COMPETITIVE ADVANTAGE

Pelican Expression Technology Platform Has a Legacy of Success and Value Creation



Platform has long history of successful production strain identification with unprecedented speed, while maintaining a success rate of >80% with complex proteins

Technology Platform Benefits



Toolbox diversity and automation enables rapid and broad exploration of expression strategies, enabling success with even the most challenging and complex proteins



Speed and success rate have direct impact on development cost and time



Significant reduction of long-term cost-of-goods



Platform has enabled integration and improved productivity of several modifications via genetic manipulation (e.g., site-specific pegylation (Ambrx), pasylation (XL-protein), fusions (teriparatide))



Track record of successful expression of novel modalities positions the platform to potentially enable *state-of-the-art* drugs relevant to the industry today and in the future



BUSINESS OVERVIEW

SEPTEMBER 2021

OMNIAB

MEETING A GLOBAL INDUSTRY NEED AND POISED FOR MASSIVE GROWTH

**ONE OF THE LARGEST GREENFIELDS
IN THE PHARMA INDUSTRY**

*>\$250 BILLION TOTAL ADDRESSABLE
MARKET FOR ANTIBODIES BY 2025*

LEADING AND PROVEN TECH

*GROWING ROSTER OF GLOBAL PARTNERS
19 CLINICAL-STAGE ANTIBODIES
FIRST PRODUCT APPROVAL THIS YEAR*

**GLOBALLY-RECOGNIZED
SCIENCE AND TEAM**

*HISTORY OF FIRSTS IN GENETIC ENGINEERING
EXPANDING TEAM OF 25 SCIENTISTS (15 PHDs)*

OMNIAB OUR PHILOSOPHY AND APPROACH

LEVERAGING OUR TECH STACK TO SERVE A FAST-GROWING AND CRITICALLY IMPORTANT INDUSTRY

We apply proprietary, AI-powered antigen generation techniques to highly-optimized next-generation transgenic animals.

We then tap into the unparalleled powers of **biological intelligence**[™] and *in vivo* maturation to generate massive numbers of target-specific antibodies.

Those antibodies are efficiently mined with validated state-of-the-art high-throughput screening technologies designed to deliver highest quality therapeutic candidates for a wide range of human diseases.

THE OMNIAB TECH STACK

AbInitio Antigen

OmniRat[®], OmniMouse[®] and OmniChicken[®]

OmniFlic[®] and OmniClic[™]

OmniTaur[™]


xPloration[®] and GEM

Discovery and Antibody Optimization
algorithm technologies and services

A Validated Platform: 19 OmniAb antibodies are in clinical development (with 1 approved and 1 awaiting approval)

OmniAb partners enjoy access to the **most comprehensive and cutting-edge** stack of antibody discovery technologies available

We believe screening the best and broadest antibody repertoires available with the most cutting-edge and highest-throughput validated screening technologies available **will deliver high quality drug candidates** for a wide range of programs...





ANTIBODY MARKET AND OPPORTUNITY

MINING ONE OF THE LARGEST GREENFIELDS IN A GROWING INDUSTRY

ANTIBODIES AND INDUSTRY DEMAND

HIGHER SUCCESS RATES FOR ANTIBODY MEDICINES DRIVE OUR INDUSTRY'S NEED FOR DISCOVERY TECHNOLOGY

Increasing Antibody Market

>\$250 Billion Total Addressable Market for Antibodies by 2025


Higher Success Rates

| Type of Drug | Likelihood of Approval at Phase 1 Stage |
|----------------------|---|
| Small molecules | 6.2% |
| Biologics/Antibodies | 11.5% |

Historical success rates for antibody classes is **nearly twice the rate** of small molecules

Substantial growth in number of new antibody therapeutics

Acceleration of Regulatory Approvals



SELECT OMNIAB PARTNERS

50 COMPANIES CURRENTLY HAVE ACCESS TO OMNIAB ANTIBODIES


MERCK

 **Genmab**

janssen 

AMGEN

 **Pfizer**

SANOFI 

 **symphogen**
a Servier Company

 **Boehringer
Ingelheim**

 **基石药业**
CSTONE
PHARMACEUTICALS

 **gloria** 誉衡生物
BIOSCIENCES


 **Takeda**

WuXi Biologics
Global Solution Provider 

OMNIAB PARTNER PROGRAMS

PROGRESSION AND PERFORMANCE

Programs by Stage of Development




>14,000 clinical patients have been or are planned to be treated with OmniAb antibodies

Substantial growth in all phases

Increases in Discovery poised to rapidly feed growth in new clinical programs and future approvals

Total Clinical Trial Starts
















Upcoming new clinical starts

Based on partner progression, projecting as many as 10 OmniAb marketing approvals by 2028

OMNIAB PARTNER PROGRAMS

LATE-STAGE PIPELINE POISED FOR GROWTH AND TWO APPROVALS IN 2021

| Partner | Program | Therapy Area | Preclinical | Phase 1 | Phase 2 | Phase 3 | BLA | Approved |
|---|--------------|--------------|--|---------|---------|---------|-----|----------|
|  誉衡生物 | Zimberelimab | Oncology | Approved for R/R classical Hodgkin's lymphoma in China | | | | | |
|   | Sugemalimab | Oncology | NMPA filed for NSCLC, approval expected in Q4'21 | | | | | |
|   | Batoclimab | Autoimmune | Phase 2/3 completion in TED and ITP Q1 '23 | | | | | |
|   | Zimberelimab | Oncology | Interim Phase 2 completion Q2' 22 | | | | | |
|   | Batoclimab | Autoimmune | Initiation of pivotal study in MG H1'22. Restart of ASCEND-GO2 and ASCEND-WAIHA in '22 | | | | | |
|  | Teclistamab | Oncology | Phase 2 data expected in '23 | | | | | |
|  | GEN1046 | Oncology | Data expected Q4 '22 | | | | | |
|  | M6233 | Oncology | Data expected Q3 '22 | | | | | |
|  | APVO436 | Oncology | Data expected in '22 | | | | | |
| Multiple | Multiple | Multiple | 10 additional Phase 1 | | | | | |
| Multiple | Multiple | Multiple | 180 additional Preclinical & Discovery | | | | | |

19 Clinical-Stage
OmniAb
Antibodies

ZIMBERELIMAB APPROVED

FIRST OMNIAB ANTIBODY APPROVAL

- On August 30, zimberelimab (GLS-010), an OmniAb-derived fully human anti-PD-1 mAb, was approved in China for the treatment of recurrent or refractory classical Hodgkin's lymphoma
 - Marks the first approval of an OmniAb-derived mAb
- In 2015, GloriaBio contracted with WuXi Biologics to discover and develop zimberelimab in China using Ligand's transgenic rat platform, OmniRat®
 - Zimberelimab entered clinic in March 2017, and NDA was submitted to China NMPA in February 2020
- GloriaBio is also investigating zimberelimab in advanced solid tumors, and was granted Breakthrough Therapy Designation for treatment of patients with recurrent/metastatic cervical cancer in March 2021
- Zimberelimab is being developed by Arcus Bioscience, in collaboration with Gilead, in North America, Europe, Japan and certain other territories through a 2017 license agreement



BUSINESS MODEL AND TECH STACK

MINING ONE OF THE LARGEST GREENFIELDS IN A GROWING INDUSTRY

OMNIAB BUSINESS MODEL

OUR *BEST-IN-CLASS* TECH STACK ALLOWS US TO SHARE IN THE SUCCESS OF OUR PARTNERS

License partnerships designed to include:

- *Technology access and collaboration/service fees*
- *Milestones*
- *Royalties on commercial sales*

We have nearly **\$1 billion in contracted milestones** (for over 300 events) with active OmniAb programs today, with continued efficient growth expected as partners expand use of the platform and as we add new partners

OMNIAB STRATEGY *NEXT THREE YEARS*

TECHNOLOGY CONTRIBUTING SIGNIFICANTLY TO GLOBAL HUMAN HEALTH

Innovation and Technology

- Continued investment in R&D to drive our innovation
- Develop new technologies and platforms to expand our offer and current partnerships

Mergers and Acquisitions

- Explore tech bolt-on acquisitions to further transform the business and enter more licenses

Portfolio Growth

- Continued expansion of use by current partners and addition of new partners
- Multiple commercial products contributing royalty revenue

Stakeholders Are Our Foundation



Team:

Strong culture; hire, develop, motivate the best



Partners:

Focus on customer service



Investors:

Superior business execution to create value




Community:

Lead with integrity and responsibility

OMNIAB HISTORY

OVER 12 YEARS OF INVESTMENT BUILT OUR *BEST-IN-CLASS* PLATFORM



Strategically built tech stack to optimally harness the unparalleled power of **BIOLOGICAL INTELLIGENCE™**

THE OMNIAB OFFERING CONTINUUM

OUR *BEST-IN-CLASS* TECH STACK AND CAPABILITIES

Antigen Design

*Antibody
Generation*

Deep Screening

Discovery

Optimization

Technology offering addresses critical industry needs and is paired with our highly specialized and efficient operation

We leverage our proprietary and differentiated technologies rather than commoditized industry services that are widely available from CROs or built into big pharma


THE OMNIAB OFFERING CONTINUUM

OUR *BEST-IN-CLASS* TECH STACK AND CAPABILITIES

Our capabilities, investment and innovation position OmniAb for near and long-term success

Antigen Design

AI-powered antigen design for challenging therapeutic targets




Antibody Generation

World-class transgenic animals **for fast discovery** of naturally-optimized human antibodies in multiple modalities




Deep Screening

Ultra-high resolution, high-speed **automated antibody selection**



Discovery

Rapid expression and specificity, epitope and affinity determination



Optimization

Next generation sequencing analysis and bioinformatics to further improve and de-risk leads

| | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | A | I | Y | C | A | - | R | D | G | W | N | S | G | S | F | D | Y | W | |
| V | . | . | . | . | . | . | K | E | T | . | . | . | . | . | . | . | Y | N | F |
| V | . | . | . | . | . | . | K | R | . | N | G | Y | A | F | . | . | . | . | . |
| . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . |
| . | . | . | . | . | . | . | K | R | . | K | G | Y | A | F | . | . | . | . | . |
| . | . | . | . | . | . | . | K | E | T | . | . | . | . | . | . | . | Y | N | F |
| . | . | . | . | . | . | . | K | E | T | . | . | . | . | . | . | . | Y | N | F |
| . | . | . | . | . | . | . | K | R | . | N | G | Y | A | F | . | . | . | . | . |
| . | . | . | . | . | . | . | K | R | . | K | G | Y | A | F | . | . | . | . | . |

THE POWER OF OMNIAB PARTNER CASE STUDIES

Partner A

Emerging Biotech



- **Novel multi-transmembrane target** for triple negative breast cancer
- All previously-known antibodies to target could only bind to denatured or fixed form, **therefore unsuitable for therapeutic use**
- **Our antigen tech** was applied to deliver mg-scale quantities of purified receptor **in native conformation** for immunization and screening
- **OmniChicken immunization then led to discovery of a large and diverse panel of fully-human antibodies** capable of binding target on live tissues

Partner B


Big Pharma



- Growth factor target, **highly conserved among mammals**
- Human version of target non-immunogenic in other rodents; **no titer achieved despite numerous immunization attempts at partner**
- Genetic knockout of target gene attempted in mice **but was lethal**
- **OmniChicken** immunization led to robust titers and diverse fully-human antibody panels
- **>90% of sequences recovered had excellent developability profiles** based on multi-parameter *in-silico* analysis

Partner C

Established Biotech



- Partner has history of success in *first-in-class* and *best-in-class* antibodies, **with large discovery group and expanding novel biology**
- Need flexible fully-human antibody discovery toolbox to **start dozens of new programs every year**
- Deep collaboration including parallel pilot testing of **next-gen rodents on active novel programs**
- Clinical candidates identified with Phase 1 and 2 data readouts in next 18 months, and **multiple candidates to enter clinical development in the coming years**

Partner D

Global Pharma



- Asia-based **global pharma player**
- **Establishing new and substantial presence in antibody space** with large investment and expansion of global antibody team
- **Selected OmniAb as core technology** to feed robust discovery and development efforts
- Developed three-way collaboration with **deep repertoire analysis to rapidly identify best binders** for bispecific antibodies

The background of the slide features a dark blue gradient with several 3D molecular models of antibodies. These models are rendered in a wireframe style, with some parts colored in red and others in grey. They are scattered across the frame, with some appearing more prominent than others, creating a sense of depth and scientific focus.

OmniAb[®]

INTELLECTUAL PROPERTY


MINING ONE OF THE LARGEST GREENFIELDS IN A GROWING INDUSTRY

OMNIAB PERFORMANCE AND IP

PARTNERS FILING PATENTS ON OMNIAB ANTIBODIES CREATE DURABLE ROYALTY STREAMS AND A LENGTHY INTELLECTUAL PROPERTY TAIL

- We maintain a broad intellectual property estate with multiple long duration patent families covering each major element of our tech stack
- Licenses are structured so that royalties are linked to the patents for the antibodies discovered with OmniAb, thereby creating a **lengthy coverage “tail”**

**Novel Antibody Patents
filed by Partners**



Now approaching **50 patent filings by our partners** claiming an OmniAb-derived antibody as primary invention, with expiries up to 2041

A detailed 3D molecular model of an antibody, showing its characteristic Y-shaped structure. The model is composed of numerous small, interconnected spheres in shades of red, orange, and grey, set against a dark blue background with a subtle, larger-scale molecular pattern.

OmniAb[®]

OUR TEAM

MINING ONE OF THE LARGEST GREENFIELDS IN A GROWING INDUSTRY

OMNIAB ESTABLISHED SCIENTIFIC LEADERSHIP

38



Bill Harriman, PhD

SVP, Antibody Discovery

Co-Founder/CSO Crystal Bioscience
Trellis, Roche, Abgenix
UCSF-Immunology, Haas MBA



Marie-Cecile Van De Lavoie, PhD, DVM

VP, Operations

Co-Founder/COO Crystal Bioscience
Origen Therapeutics, Inventor germ cell technology
Fulbright Scholar, UCSF, Utrecht, Guelph, Cornell



Christel Iffland, PhD

VP, Antibody Technology

Co-inventor Avelumab
EMD Serono
Dana Farber, Albert Einstein College



Shelley Izquierdo, PhD

Director, Antibody Discovery

Crystal Bioscience, Trellis
UC Berkeley



Phil Leighton, PhD

Sr. Director, Molecular Biology

Genetic Engineering Lead at
Crystal Bioscience and Origen
Princeton, UCSF



Bob Chen, PhD

Director, Systems Engineering

Co-Founder and CTO xCella Bio
Stanford Bioengineering



Ellen Collarini, PhD

Sr. Director, Cell Biology

Crystal Bioscience, Trellis, Roche
Univ. Michigan, Univ. College-London



NON-DEAL ROADSHOW

SEPTEMBER 2021

Nasdaq: LGND